Alpha-Adrenergic Antagonists: Clinical Examples
Alpha-adrenergic antagonists are divided into selective alpha-1 blockers (alfuzosin, doxazosin, tamsulosin, terazosin, prazosin) and nonselective alpha blockers (phenoxybenzamine, phentolamine, labetalol), with the selective alpha-1 agents being the primary therapeutic options for benign prostatic hyperplasia and hypertension.
Selective Alpha-1 Adrenergic Antagonists
The most clinically relevant alpha-adrenergic antagonists are the selective alpha-1 blockers, which include:
- Alfuzosin
- Doxazosin
- Tamsulosin
- Terazosin
- Prazosin
These agents work by selectively blocking alpha-1 adrenergic receptors on prostatic smooth muscle and vascular smooth muscle, resulting in relaxation and reduced resistance 1. The AUA guidelines specifically recommend alfuzosin, doxazosin, tamsulosin, and terazosin as appropriate treatment options for lower urinary tract symptoms secondary to benign prostatic hyperplasia, noting that all four have equal clinical effectiveness despite slight differences in adverse event profiles 1.
Dosing and Clinical Use
For BPH management, typical dosing includes:
- Doxazosin: titrated up to 8 mg daily
- Tamsulosin: 0.4-0.8 mg daily
- Terazosin: titrated up to 10 mg daily 1
Prazosin has insufficient data to support its routine use for BPH according to guideline recommendations, though it remains a prototype selective alpha-1 antagonist used in other contexts 1.
Adverse Effects
The primary adverse events include orthostatic hypotension, dizziness, asthenia (tiredness), ejaculatory dysfunction, and nasal congestion 1. Notably, tamsulosin has a lower probability of orthostatic hypotension but higher probability of ejaculatory dysfunction compared to other alpha-1 blockers 1.
Nonselective Alpha Adrenergic Antagonists
Phenoxybenzamine
Phenoxybenzamine is a long-acting nonselective alpha-adrenergic antagonist that is the most commonly used agent for preoperative preparation in pheochromocytoma 2. It blocks both alpha-1 and alpha-2 receptors and exhibits two-component binding kinetics 3.
For pheochromocytoma management, phenoxybenzamine is started at 10 mg twice daily and titrated upward to as much as 300-400 mg daily in divided doses until blood pressure is controlled or intolerable side effects develop 2.
Data are insufficient to support phenoxybenzamine use for BPH treatment 1.
Phentolamine
Phentolamine is a nonselective alpha receptor antagonist used specifically for hypertensive emergencies induced by catecholamine excess, including:
- Pheochromocytoma
- MAO inhibitor interactions
- Cocaine toxicity
- Amphetamine overdose
- Clonidine withdrawal 4, 5
The IV bolus dose is 5 mg, with additional boluses every 10 minutes as needed 4, 5. It can also be used intraoperatively during pheochromocytoma resection 2.
Labetalol
Labetalol is a combined alpha-1 and nonselective beta receptor antagonist (hybrid drug), though it functions predominantly as a beta blocker with much weaker alpha-1 antagonistic activity 6. For hypertensive emergencies, the initial dose is 0.3-1.0 mg/kg (maximum 20 mg) via slow IV injection every 10 minutes, or 0.4-1.0 mg/kg/h IV infusion up to 3 mg/kg/h 4, 5.
Labetalol is contraindicated in reactive airways disease or COPD and should not be given to patients with second- or third-degree heart block or bradycardia 4, 5.
Important Clinical Considerations
Drug Interactions and Contraindications
When managing hypertension in patients already taking tricyclic antidepressants (e.g., amitriptyline) or certain antipsychotics (e.g., chlorpromazine, risperidone), adding alpha blockers may not provide additional benefit since these psychotropic medications already possess high alpha-1 adrenoceptor affinity similar to or higher than prescribed alpha blockers 3.
Cardiovascular Concerns
In men with hypertension and cardiac risk factors, doxazosin monotherapy was associated with higher incidence of congestive heart failure compared to other antihypertensive agents 1. Therefore, using an alpha blocker for lower urinary tract symptoms should not be assumed to constitute optimal management of concomitant hypertension, and separate hypertension management may be required 1.
Metabolic Effects
Alpha-1 blockers have beneficial effects on lipid profiles, tending to decrease triglycerides and total cholesterol while increasing HDL cholesterol 7, 8. This makes them particularly appropriate for diabetic hypertensive patients and those with elevated serum lipids 8.